You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Blood and immune system conditions
  5. Blood and bone marrow cancers

Bortezomib and thalidomide for the first‑line treatment of multiple myeloma

  • Technology appraisal guidance
  • Reference number: TA228
  • Published:  27 July 2011
  • Guidance
  • Tools and resources
  • Information for the public
  • History

Multiple myeloma (first line) - bortezomib and thalidomide: appendix A - GE decision paper - March 2015

Multiple myeloma (first line) - bortezomib and thalidomide: appendix A - GE decision paper - March 2015 Multiple myeloma (first line) - bortezomib and thalidomide: appendix A - GE decision paper - March 2015
08 April 2014
(182.28 Kb 53 sec)

Adobe Acrobat reader required.

  Adobe Acrobat reader required.

This page was last updated: 02 April 2015

Back to top